Amicus Therapeutics Inc., of Cranbury, N.J., added Craig A. Wheeler to its board.
Aprea AB, of Stockholm, named Christian S. Schade president and CEO. He will be based in Boston.
Arena Pharmaceuticals Inc., of San Diego, appointed Kevin R. Lind executive vice president and chief financial officer.
Collegium Pharmaceutical Inc., of Canton, Mass., added John A. Fallon to its board.
Cumberland Pharmaceuticals Inc., of Nashville, Tenn., added Caroline Young to its board.
Cytomx Therapeutics Inc., of South San Francisco, added John "Chip" A. Scarlett to its board.
Eli Lilly and Co., of Indianapolis, named Aarti Shah senior vice president and chief information officer.
Genocea Biosciences Inc., of Cambridge, Mass., added Ron Cooper to its board.
Intercept Pharmaceuticals Inc., of New York, appointed Sandip Kapadia chief financial officer.
Minoryx Therapeutics SL, of Mataró, Spain, appointed Uwe Meya chief medical officer.
Northwest Biotherapeutics Inc., of Bethesda, Md., appointed Martin "Mac" Cheever, Alfredo Quiñones-Hinojosa, Jerome Galon, Samir N. Khleif, and John Smyth to its scientific advisory board.
Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., added Bradley Campbell to its board.
Promethera Biosciences SA, of Mont-Saint-Guibert, Belgium, named Torsten Hombeck chief commercial and strategy officer, and appointed Christof Hettich board chairman.
PTC Therapeutics Inc., of South Plainfield, N.J., added Dawn Svoronos to its board.
Valeant Pharmaceuticals International Inc., of Laval, Quebec, named Thomas W. Ross Sr. lead independent director.
Verastem Inc., of Boston, added Bruce J. Wendel to its board, named Michael Kauffman lead director, and appointed Stephen Sherwin to its clinical and scientific advisory board.
X4 Pharmaceuticals Inc., of Cambridge, Mass., appointed John K. Celebi chief operating officer.
Xbiotech Inc., of Austin, Texas, named Trey Benson commercial head.